Sharon Worcester is an award-winning medical journalist for MDedge News. She has been with the company since 1996, first as the Southeast Bureau Chief (1996-2009) when the company was known as International Medical News Group, then as a freelance writer (2010-2015) before returning as a reporter in 2015. She previously worked as a daily newspaper reporter covering health and local government. Sharon currently reports primarily on oncology and hematology. She has a BA from Eckerd College and an MA in Mass Communication/Print Journalism from the University of Florida. Connect with her via LinkedIn and follow her on twitter @SW_MedReporter.
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
- Author:
- Sharon Worcester
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
News
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
- Author:
- Sharon Worcester
Gadolinium-based contrast agents used for MRI will now carry a warning regarding potential retention in the bodies and brains of treated patients...
News
CRB-410 update: Multiple myeloma response rates remain high with bb2121 CAR T-cell therapy
- Author:
- Sharon Worcester
ATLANTA – A novel CAR T-cell therapy that targets BCMA shows promising efficacy and safety in heavily pretreated patients with relapsed/refractory...
Video
VIDEO - New lymphoma drug approvals: Clinical use, future directions
- Author:
- Sharon Worcester
ATLANTA - At the ASH annual meeting, FDA representatives and clinicians discussed new lymphoma drug approvals and their use in the real-world...
Video
VIDEO: Joint FDA-ASH session highlights new AML drugs
- Author:
- Sharon Worcester
ATLANTA – During a special interest session at the ASH annual meeting, FDA representatives and clinicians discussed new drugs available for the...
News
CLARITY: Ibrutinib/venetoclax combo results look promising for relapsed/refractory CLL
- Author:
- Sharon Worcester
ATLANTA – Ibrutinib/venetoclax is well tolerated and shows promise for relapsed/refractory CLL, according to early CLARITY feasibility trial...
News
HAVEN 2: Emicizumab represents new standard of care for hemophilia A with inhibitors
- Author:
- Sharon Worcester
ATLANTA – Emicizumab safely prevents or substantially reduces bleeds in children with hemophilia A with inhibitors.
News
DNA vaccine + PD-1 blockade shows promise in mCRPC
- Author:
- Sharon Worcester
NATIONAL HARBOR, MD. – Combining PD-1 pathway inhibition with a DNA vaccine led to antitumor changes in mCRPC patients in a randomized clinical...
News
First-in-class glutaminase inhibitor combats anti-PD-1/PD-L1 resistance
- Author:
- Sharon Worcester
NATIONAL HARBOR, MD. – Responses in melanoma patients who were progressing on nivolumab at study entry and who were refractory to multiple prior...
News
ENCORE 601 study: Entinostat shows promise in NSCLC
- Author:
- Sharon Worcester
Entinostat given in combination with pembrolizumab demonstrated antitumor activity and acceptable safety in patients with NSCLC in the phase 1b/2...
News
GSI may boost BCMA CAR T-cell therapy efficacy in myeloma
- Author:
- Sharon Worcester
Gamma secretase inhibition may lead to improved outcomes in multiple myeloma patients treated with BCMA-specific CAR T-cell therapy.
News
CD22 CAR activity in B-ALL highlights promise of multispecific CARs
- Author:
- Sharon Worcester
NATIONAL HARBOR, MD. – A new CD22-targeted CAR demonstrated clinical activity in relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)...
News
CAR T-cell therapy: Moving from cost to value
- Author:
- Sharon Worcester
Cost and value issues temper CAR T-cell therapy enthusiasm.
News
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancers
- Author:
- Sharon Worcester
Nivolumab has promising activity in mismatch repair–deficient noncolorectal cancers, according to preliminary findings from the NCI-MATCH trial....
News
CheckMate 214: Updated results for RCC focus on PD-L1 expression, QOL
- Author:
- Sharon Worcester
NATIONAL HARBOR, MD. – Benefit from combination immune checkpoint inhibitor treatment for renal cell carcinoma patients was greatest with PD-L1–...